MRC Technology and NYU School of Medicine Collaborate
News Apr 23, 2015
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown).
Drs Bruce Cronstein and Kathryn Moore of NYU School of Medicine have identified key proteins expressed on the surface of osteoclasts in the progression of inflammatory osteolysis. MRC Technology has extensive experience in antibody engineering and under the agreement will generate lead antibodies for testing in osteolysis models, before delivering a candidate antibody with acceptable efficacy in vivo.
Dr Nadim Shohdy, Director, Drug Discovery Partnerships at NYU School of Medicine said: “Osteolysis affects about 20% of patients with orthopaedic prostheses, resulting in implant loosening and the need for revision surgeries. By combining the expertise of NYU School of Medicine in this area with that of MRC Technology, a leader in the discovery and development of antibody drugs, we aim to develop efficacious antibodies for patients with osteolysis that currently have few therapy options.”
Dr John Kelly, Associate Director, Business Development, MRC Technology said: “NYU School of Medicine has done extensive research and holds various patents for inhibiting osteolysis. Combined with our successful track record in antibody development to create therapies for a number of debilitating conditions, we are positive that we can help bring new treatments to patients.”
Financial terms have not been disclosed.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic DiscoveryNews
A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.READ MORE